CN104644666A - Medicine for treating coronary heart disease - Google Patents
Medicine for treating coronary heart disease Download PDFInfo
- Publication number
- CN104644666A CN104644666A CN201410292155.7A CN201410292155A CN104644666A CN 104644666 A CN104644666 A CN 104644666A CN 201410292155 A CN201410292155 A CN 201410292155A CN 104644666 A CN104644666 A CN 104644666A
- Authority
- CN
- China
- Prior art keywords
- medicine
- heart disease
- coronary heart
- nifedipine
- simvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine for treating a coronary heart disease, and relates to the technical field of medical treatment. The medicine is prepared from the following raw materials in parts by weight: 55%-60% of chondroitin sulfate, 20%-30% of nifedipine and 15%-20% of simvastatin. The medicine disclosed by the invention is significant in treatment effect on the coronary heart disease and free of reoccurrence.
Description
Technical field
The present invention relates to field of medical technology, especially a kind of medicine for the treatment of coronary heart disease.
Background technology
Coronary heart disease is frequently-occurring disease common clinically, modern medicine is thought, coronary heart disease causes coronary stricture because coronary atherosclerosis or thrombosis are attached on coronary blood tube wall, reduced by blood flow coronarius, when cardiac load increases suddenly, blood volume is needed to increase, exceed the compensatory capacity of coronary artery blood supply, or need blood volume not increase, but coronary spasm, decrease blood flow, or above-mentioned factor exists simultaneously, all can cause palpitate quickly, ischemia, anoxia and angina pectoris occurs.
The method of domestic and international treatment coronary heart disease is various, comprises the formation of coronary artery dilator and anti-tampon and the gathering of thrombosis, but the curative effect of these methods is unstable, the easy recurrent exerbation of the state of an illness.
Summary of the invention
The object of this invention is to provide a kind of medicine for the treatment of coronary heart disease, this medicine is by chondroitin sulfate, and nifedipine and simvastatin combined therapy coronary heart disease, its curative effect is more stable.
In order to solve the problem, the technical solution used in the present invention is: the medicine of this treatment coronary heart disease, is made up of the raw material of following percentage by weight: chondroitin sulfate 55% ~ 60%, nifedipine 20% ~ 30%, simvastatin 15% ~ 20%;
Described drug oral tablet;
The preparation method of the medicine of described treatment coronary heart disease is: take each raw material according to percentage by weight, pulverizes, and crosses 200 order molecular sieves, conventionally makes oral tablet.
Owing to have employed technique scheme, the present invention compared with prior art has following beneficial effect:
Medicine of the present invention adopts chondroitin sulfate, nifedipine and simvastatin combined therapy coronary heart disease, and curative effect is fast, and short treating period, curative effect is more stable, not easily recurs.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1
Respectively by chondroitin sulfate, nifedipine, simvastatin is pulverized, and cross 200 order molecular sieves, get 550 grams of chondroitin sulfate powder, 300 grams of nifedipine powder, 150 grams of simvastatin powder, mix homogeneously, makes oral tablet, and every tablet is 50 milligrams.
Embodiment 2
Respectively by chondroitin sulfate, nifedipine, simvastatin is pulverized, and cross 200 order molecular sieves, get 600 grams of chondroitin sulfate powder, 200 grams of nifedipine powder, 200 grams of simvastatin powder, mix homogeneously, makes oral tablet, and every tablet is 50 milligrams.
Embodiment 3
Respectively by chondroitin sulfate, nifedipine, simvastatin is pulverized, and cross 200 order molecular sieves, get 600 grams of chondroitin sulfate powder, 250 grams of nifedipine powder, 150 grams of simvastatin powder, mix homogeneously, makes oral tablet, and every tablet is 50 milligrams.
Clinical trial:
The present invention accepts patients with coronary heart disease 316 example for medical treatment, wherein, man 167 example, female 149 example, patient age is 45 years old ~ 76 years old, the course of disease 1 ~ 23 year; All patients every day three times, the medicine prepared by each 2 oral the present invention.15 days courses for the treatment of, the treatment phase is 45 days.
Through the observation treatment of 45 days, in 316 routine patients, cure patient and reach 283 examples, the state of an illness is clearly better and reaches 15 examples, and the patient that fails to respond to any medical treatment is 18 examples.
In sum, this curative effect of medication is definite, and therapeutic effect is stablized, and total effective rate reaches 94.3%.This medicine has significant curative effect to coronary heart disease, and patient generally feels that symptom obviously alleviates or disappears after taking medicine 5 days, and its blood pressure, blood fat, blood glucose etc. also improve significantly.
Claims (1)
1. treat a medicine for coronary heart disease, it is characterized in that, be made up of the raw material of following percentage by weight: chondroitin sulfate 55% ~ 60%, nifedipine 20% ~ 30%, simvastatin 15% ~ 20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410292155.7A CN104644666A (en) | 2014-06-26 | 2014-06-26 | Medicine for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410292155.7A CN104644666A (en) | 2014-06-26 | 2014-06-26 | Medicine for treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104644666A true CN104644666A (en) | 2015-05-27 |
Family
ID=53236636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410292155.7A Pending CN104644666A (en) | 2014-06-26 | 2014-06-26 | Medicine for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104644666A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282160A (en) * | 2022-07-04 | 2022-11-04 | 滨海宇美科技有限公司 | Compound simvastatin sodium chondroitin sulfate capsule and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884634A (en) * | 2010-07-27 | 2010-11-17 | 北京华禧联合科技发展有限公司 | Composition for treating cardiovascular diseases |
| CN102018867A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Medical composition containing chondroitin sulfuric acid and/or medical salt thereof and garlic oil |
| CN102579442A (en) * | 2012-03-15 | 2012-07-18 | 济南龙华医药技术有限公司 | Compound preparation containing benidipine hydrochloride and atorvastatin calcium and application for compound preparation |
| CN103239725A (en) * | 2012-10-29 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | Compound preparation for treating cardiovascular and cerebrovascular diseases |
-
2014
- 2014-06-26 CN CN201410292155.7A patent/CN104644666A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018867A (en) * | 2009-09-19 | 2011-04-20 | 菲伯纳生物医药有限责任公司 | Medical composition containing chondroitin sulfuric acid and/or medical salt thereof and garlic oil |
| CN101884634A (en) * | 2010-07-27 | 2010-11-17 | 北京华禧联合科技发展有限公司 | Composition for treating cardiovascular diseases |
| CN102579442A (en) * | 2012-03-15 | 2012-07-18 | 济南龙华医药技术有限公司 | Compound preparation containing benidipine hydrochloride and atorvastatin calcium and application for compound preparation |
| CN103239725A (en) * | 2012-10-29 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | Compound preparation for treating cardiovascular and cerebrovascular diseases |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282160A (en) * | 2022-07-04 | 2022-11-04 | 滨海宇美科技有限公司 | Compound simvastatin sodium chondroitin sulfate capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104644666A (en) | Medicine for treating coronary heart disease | |
| CN104173477B (en) | A kind of for analgesic pharmaceutical composition and preparation method thereof | |
| US20220332796A1 (en) | Fused polypeptide with multifunctional activities and use thereof | |
| CN101070338A (en) | Tanshinone IIA potassium sulfonate for preparing medicine for preventing and treating myocardial ischemia and cerebral ischemia and anoxia | |
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| CN101785781B (en) | Medicine combination of levoamlodipine or medicinal salt of levoamlodipine and auricularia auricula polysaccharide, and application thereof | |
| CN101804075A (en) | Application of starfishes to preparation of medicament for treating osteoporosis | |
| CN104490923B (en) | healing ointment | |
| CN102755319B (en) | Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof | |
| CN107693598A (en) | A kind of compound preparation of reducing blood lipid and preparation method thereof | |
| CN105348171B (en) | A kind of pharmaceutical composition treating knee osteoarthritis | |
| CN103585411B (en) | A kind of medicament for the treatment of hemorrhoid | |
| CN1943573A (en) | Use of vitamin C and arginine composition in anti-anoxic medicine and health product | |
| Osovska et al. | Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block-a case report | |
| CN109172600B (en) | A kind of medical composition and its use | |
| CN102755324B (en) | Pharmaceutical composition containing prasugrel and rosuvastatin, and purpose thereof | |
| CN104644665A (en) | Medicine for treating arthritis | |
| CN1682715A (en) | Anti-anoxia medicinal composition | |
| CN1084627C (en) | Traditional Chinese medicinal plaster for treating psoriasis | |
| CN105769882A (en) | Pharmaceutical composition for inhibiting thrombosis and application of pharmaceutical composition | |
| CN104740029B (en) | A kind of pharmaceutical composition for the treatment of gout | |
| CN100434080C (en) | A medicine for treating dermatosis | |
| CN101073565A (en) | Use of arginine and taurine composition in anti-hypoxia medicine and health food | |
| Kapustnik et al. | The use of herbal medicines with antiviral activity of plant origin for the treatment of diseases caused by COVID-19 infection | |
| CN102742843A (en) | Health-care functional food for preventing hemorrhoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150527 |